by Sanofi
by Janssen with support from Aurora
by Lundbeck UK Limited and Teva UK Limited
by Teva UK Limited and Lundbeck Limited with support from Bamboo Medical Communications
by Lundbeck UK Limited and Teva UK Limited
In June 2011 the growth rate for Azilect started to decline. Parkinson’s disease (PD) Specialists were occasionally prescribing Azilect but it was not their drug of choice and the majority did not expect to increase their prescribing. A mature brand required revitalising, although a national didactic approach was not optimal because territory market share varied significantly.
By May 2012:
This was a very well thought through campaign with effective segmentation and targeting that lead to good outcomes and addressed issues in line with the overall brand strategy.